Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva PharmafiledCriticalTeva Pharma
Publication of UY34981ApublicationCriticalpatent/UY34981A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Método para inhibir de manera preferencial la monoamina oxidasa A (MAOA) en el cerebro de un sujeto, con relación a lo que podría observarse en el intestino del sujeto, que comprende administrarle por vía parenteral al sujeto una formulación de liberación controlada que comprende una cantidad eficaz para el uso terapéutico de rasagilina o de una sal farmacéuticamente aceptable de ésta.Method for preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject, in relation to what could be observed in the intestine of the subject, which comprises administering to the subject parenterally a controlled release formulation comprising an amount effective for the therapeutic use of rasagiline or a pharmaceutically acceptable salt thereof.
UY34981A2012-03-082013-08-15
PARENTERAL FORMULATIONS OF RASAGILINA
UY34981A
(en)
Pharmaceutical composition comprising dimethyl fumarate; Preparation method; capsule comprising microtablets of dimethyl fumarate; method for the treatment, prophylaxis or improvement of multiple sclerosis.
A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.
Compounds derived from pyrrole [3,4-b] pyridin-5-one, inhibitors of pi3k; pharmaceutical composition comprising them; and use for the treatment of diseases such as Alzheimer's, epilepsy, multiple sclerosis, Parkinson's, among others.
Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition.